Champions Oncology: One Quarter of Data Revenue Just Out-Earned an Entire Fiscal Year

A nano-cap CRO's data-licensing option finally prints — but the tape and the Corellia clock both say 'show me more'

CSBR · Earnings Call · 2026-09-10

The quarter the data business finally answered

For a decade Champions Oncology pitched a simple asymmetry: it runs the tumor models the industry depends on, and that same work generates a clinically-annotated, patient-derived dataset that AI-hungry sponsors cannot easily replicate. The problem was never the thesis — it was the proof. In fiscal Q1 2027 the proof finally arrived: data licensing revenue of $893,000 in a single quarter, more than the whole prior fiscal year. As CEO Rob Brainin put it, “we generated more data revenue in this 1 quarter than in all of fiscal 2026, reflecting the broader base of customers we spent the last year building.” — Robert Brainin, Chief Executive Officer · 2026-09-10 The keyword evidence corroborates a genuine narrative shift, not just a good print. broader base of customers is newly prominent this quarter, and the company's editorial set has migrated from data business — a top-10 theme in 20251 and 20253 — toward Data licensing revenue and data initiatives. In fact 'data business' is the single sharpest company-keyword decliner this quarter: the language of building a data platform has given way to the language of monetizing one. That is exactly what an investor wants to see from an option that had been theoretical for so long. That reframing also ties Champions to the market's dominant macro theme. The global keyword board for the last twelve quarters is dominated by the compute-and-data buildout — AI ARR, data centers, GPU clusters. Champions is a peripheral, tiny player in that wave, but a differentiated one. As Brainin framed it:

As sponsors lean harder on AI and machine learning to make development decisions, the constraint isn't the model. It's the data underneath it. Deeply characterized clinically annotated, patient-derived data is scarce, and we have it.
Robert Brainin, Chief Executive Officer · 2026-09-10

Margins: the operating leverage finally showing up

The second real change is cost structure. Revenue rose ~9% to $15.2 million, but the better story was margin. Gross margin reached 50.8%, up 9.6pp from the prior year, and oncology services margin specifically climbed to 51% from 43%. The driver was concrete: “Cost of oncology revenue declined by approximately $500,000 to $7.5 million from $8 million a year ago despite the increase in revenue” — David Miller, Chief Financial Officer · 2026-09-10, mainly from bringing third-party radiolabeling in-house. This is the payoff on the 'investment year' set-up. It also validates prior guidance. On the December call, CFO David Miller sketched this exact range: “I think this is really where we see the margin for the service business being in the 50%, 52%, even a little bit higher range, all things remaining equal.” — David Miller, Chief Financial Officer · 2025-12-15 Delivered. The company recorded its fifth consecutive quarter of positive adjusted EBITDA ($671K versus $59K a year ago), with total revenue of $15.2M and a GAAP net loss trimmed to roughly $426K from $527K. Note the fundamentals block lags this print — its latest v= is a stale $14M with the operating-margin shape only just turning — so the just-reported quarter is better than the trailing data shows.The tape disagrees — and Corellia stays a maybe Despite the clean beat, the market is unimpressed. CSBR is down ~14% over the last 90 days and sits roughly 24% below its June 2026 peak; the full history is a bruising -46.9% since 2010. At an ~$84 million market cap, price-to-revenue is 1.4x, down from a 9x peak in 2018. Investors are treating the data upside as optionality, not earnings power. And the biggest optionality of all — Corellia, the wholly-owned therapeutics subsidiary — still refuses to be dated. “I'm not going to put a date on any outcome for the same reasons I gave in July.” — Robert Brainin, Chief Executive Officer · 2026-09-10 The related theme (resources towards Corellia) shows up this quarter but only at the margins of the top-30 set, versus when 'Corellia' itself spiked hard in 20232. This is a recurring, unresolved thread: on the September 2025 call management conceded “it's still early, and it's premature to predict the exact size and success of this opportunity.” — Robert Brainin · 2025-09-15 The story keeps its optionality without a catalyst date. The cross-section makes the contrast pop. The recent reporter cohort is awash in agentic-AI and data-center language (ORCL's 'AI Data Platform', ADBE's agentic software), while the clinical names showing up in 90-day advancers cluster around trial readouts. Champions sits awkwardly between the two: a services business whose service business funds a data/analytics bet. The change this quarter is real — one quarter of data revenue beating a full year is not nothing — but it is small in absolute dollars, and the market wants more signed deals before it re-rates a nano-cap that has spent years disappointing. Three quarters left in fiscal '27 to prove it out.